Achaogen Questioning Whether Others Will Pursue LPAD Pathway After Zemdri Misses Out

Achaogen can take solace in US FDA's approval of the aminoglycoside antibacterial for the treatment of complicated urinary tract infections, but the limited use indication for bloodstream infections was rejected.